Our findings imply that exploiting PFKFB3 as an autophagy flux mediator for therapeutic purposes could represent a novel combination treatment regimen against lung cancer tumors with intrinsic or acquired resistance to EGFR TKIs. The gene discussed is PFKFB3; the disease is lung cancer.